54509-63-6Relevant articles and documents
LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE
-
Paragraph 0229; 0231, (2018/03/01)
Shown are a liquid crystal compound satisfying at least one of physical properties such as high stability to heat and light, a high clearing point (or high maximum temperature), low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy, large negative dielectric anisotropy, a suitable elastic constant and satisfactory compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound and a liquid crystal display device including the composition. A compound is represented by formula (1), a liquid crystal composition contains the compound, or the like.
LIQUID CRYSTALLINE COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT EACH COMPRISING SAME
-
Page/Page column 37-38, (2012/01/11)
The invention provides a liquid crystal compound having general physical properties necessary for a liquid crystal compound, that is to say, stability to heat, light or the like, a small viscosity, a suitable value of refractive index anisotropy, a suitable value of dielectric anisotropy, steep characteristics electro-optic characteristics, a wide temperature range of a nematic phase and an excellent compatibility with other liquid crystal compounds, and a liquid crystal compounds especially having a wide temperature range of a nematic phase. A compound represented by formula (1). For example, R1 and R2 are each independently alkyl having 1 to 9 carbons or alkenyl having 2 to 9 carbons, alkoxy having 1 to 8 carbons or alkenyloxy having 2 to 8 carbons; Q1 and Q4 are each independently fluorine or chlorine; Q2 and Q3 are each independently hydrogen, fluorine or chlorine, and one of Q2 and Q3 is hydrogen; Z is -CH2O or -COO-; and h is 1 or 2.
Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
-
Page 127, (2010/02/10)
This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A1, A2, Y, E1, E2, E3, and Rx are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.